APA (7th ed.) Citation

N, K., N, Y., K, M., H, H., S, Y., T, K., . . . A, U. (2014). Successful treatment of bortezomib-refractory multiple myeloma derived from monoclonal gammopathy of undetermined significance with dose-adjusted lenalidomide therapy in a patient with concomitant end-stage renal disease due to diabetic nephropathy requiring haemodialysis. CEN case reports, 3(1), 24. https://doi.org/10.1007/s13730-013-0078-x

Chicago Style (17th ed.) Citation

N, Kawano, et al. "Successful Treatment of Bortezomib-refractory Multiple Myeloma Derived from Monoclonal Gammopathy of Undetermined Significance with Dose-adjusted Lenalidomide Therapy in a Patient with Concomitant End-stage Renal Disease Due to Diabetic Nephropathy Requiring Haemodialysis." CEN Case Reports 3, no. 1 (2014): 24. https://doi.org/10.1007/s13730-013-0078-x.

MLA (9th ed.) Citation

N, Kawano, et al. "Successful Treatment of Bortezomib-refractory Multiple Myeloma Derived from Monoclonal Gammopathy of Undetermined Significance with Dose-adjusted Lenalidomide Therapy in a Patient with Concomitant End-stage Renal Disease Due to Diabetic Nephropathy Requiring Haemodialysis." CEN Case Reports, vol. 3, no. 1, 2014, p. 24, https://doi.org/10.1007/s13730-013-0078-x.